CSBio CSBio

X
[{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"DanCann Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tetra Bio-Pharma Signs a Definitive Distribution Agreement with DanCann Pharma to Monetize Its Dronabinol and Botanical Product Portfolios","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Tetra BioPharma"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Research Reveals Reduction in Hospitalization Rates, Length of Stay and Health Care Costs When Treating OIC with FDA-Approved Prescription Medications","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Bausch Health"},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"STADA Arzneimittel","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"European Pharmaceutical Company STADA and MediPharm Labs Begin First Sales in Germany Under Exclusive Agreement","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"MediPharm Labs"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"REDUVO\u2122 Marketing Approval on the Right Path","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"December 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Tetra BioPharma"},{"orgOrder":0,"company":"Altius Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Devonian Announces that its Subsidiary, Altius, Launches Authorized Generic of Dexlansoprazole (Dexilant\u00ae) in Canada","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"February 2024","url1":"","url2":"","graph1":"Small molecule","graph2":"Altius Healthcare"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            As a result of agreement, patients in Germany are now able to access GMP-certified quality medical cannabis from STADA through local pharmacies under the brand – CannabiSTADA (cannabidiol), distributed through STADAPHARM, a direct subsidiary of STADA.

            Lead Product(s): Cannabidiol,Tetrahydrocannabinol

            Therapeutic Area: Gastroenterology Product Name: CannabiStada

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: STADA Arzneimittel

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement April 01, 2021

            Medipharm CB

            TMF Summit 2024

            Not Confirmed

            envelop Contact Supplier

            Details:

            Dexilant-Generic (dexlansoprazole) is a proton pump inhibitor (PPI) indicated for healing of all grades of erosive esophagitis (EE), maintaining healing of EE and relief of heartburn & treating heartburn associated with symptomatic non-erosive GERD.

            Lead Product(s): Dexlansoprazole

            Therapeutic Area: Gastroenterology Product Name: Dexilant-Generic

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 27, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            REDUVO™ is a soft gel capsule used to treat chemotherapy-induced nausea and vomiting (CINV). It is also used to treat weight loss and severe nausea in people living with HIV infection.

            Lead Product(s): Tetrahydrocannabinol

            Therapeutic Area: Gastroenterology Product Name: Reduvo

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 22, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            RELISTOR subcutaneous injection (methylnaltrexone bromide), an opioid antagonist indicated for treatment of opioid-induced constipation, The subgroup of patients in OIC-Rx cohort received RELISTOR had 0.7 fewer inpatient days per OIC ED encounter versus No-OIC-Rx cohort.

            Lead Product(s): Methylnaltrexone Bromide

            Therapeutic Area: Gastroenterology Product Name: Relistor

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 24, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            DanCann Pharma will exclusively distribute Tetra Bio's Reduvo™ Adversa®, QIXLEEF™ and ENJOUCA™ in Denmark, Norway, Sweden, Finland, and Germany.

            Lead Product(s): Tetrahydrocannabinol

            Therapeutic Area: Gastroenterology Product Name: Reduvo Adversa

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: DanCann Pharma

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement May 05, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY